Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Whitehall-Robins

This article was originally published in The Tan Sheet

Executive Summary

Association between cough products - "including Robitussin CF" - and increased risk of lung infection or airway blockage "has not been scientifically established," OTC marketer declares in response to August Consumer Reports on Health article. CR review of OTC safety noted Whitehall's product does not carry label warnings on possible risk (1"The Tan Sheet" Aug. 13, In Brief). "Any reported link between cough products and lung infection/airway blockage is anecdotal at best," Whitehall maintains, adding it is "unfair and misleading to single out Robitussin CF as potentially causing these complications." Firm also defends warning language on Advil Cold & Sinus, which was cited by CR

You may also be interested in...



OTC safety

Whitehall-Robins' Robitussin CF labeling does not indicate OTC may increase risk of lung infection and airway blockage, while Advil Cold & Sinus labeling fails to note it may reduce effectiveness of certain antihypertensive drugs, according to August Consumer Reports On Health review of OTC drug safety. Article advises consumers be cognizant of side effects, over-dosing, misdiagnosing, allergies and drug interactions, noting "nearly every OTC drug poses some risks, especially when taken too often, in high doses or with the wrong food, drinks or medications." CR notes exceeding heartburn drug dosage can cause agitation, confusion; acetaminophen overdoses can lead to liver poisoning

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS093023

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel